Hikma launches 100th injectable
Hikma Pharmaceuticals is marking the launch of its 100th injectable product with the U.S. introduction of its vancomycin hydrochloride for injection. The product is available in 5-g, 10-g and 750-mg dosage strengths.
“Vancomycin hydrochloride for injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it’s another important addition to our growing U.S. portfolio,” said Dan Motto, Hikma executive vice president of commercial and development, injectables.
The drug is indicated to treat infections caused by susceptible strains of methicillin-resistant staphylococci, patients who can’t receive or haven’t responded to other treatments for vancomycin-susceptible organisms and treatment of staphylococcal endocarditis, among other infections.
Sales for the product in the three dosage strengths Hikma is offering were $247 million for the year ended February, according to IQVIA data.
“Vancomycin hydrochloride for injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it’s another important addition to our growing U.S. portfolio,” said Dan Motto, Hikma executive vice president of commercial and development, injectables.
The drug is indicated to treat infections caused by susceptible strains of methicillin-resistant staphylococci, patients who can’t receive or haven’t responded to other treatments for vancomycin-susceptible organisms and treatment of staphylococcal endocarditis, among other infections.
Sales for the product in the three dosage strengths Hikma is offering were $247 million for the year ended February, according to IQVIA data.